Introduction to GLP-1 Agonists
GLP-1 (Glucagon-Like Peptide-1) agonists mimic the effects of the naturally occurring incretin hormone GLP-1, playing a crucial role in glucose homeostasis and appetite regulation.
Semaglutide
**CAS Number:** 910463-68-2 **Half-life:** ~7 days (weekly dosing)
Research Findings (STEP Trials) - Average weight loss: 15-17% - Improved glycemic control - Cardiovascular benefits
Tirzepatide (Dual GIP/GLP-1 Agonist)
**CAS Number:** 2023788-19-2 **Mechanism:** Activates both GLP-1 and GIP receptors
Research Results (SURMOUNT Trials) - Weight loss up to 22% - Superior to GLP-1 monotherapy
Retatrutide (Triple Agonist)
**CAS Number:** 2381089-83-2 **Mechanism:** GIP + GLP-1 + Glucagon receptors
Early Results - Weight loss up to 24% at highest doses - Enhanced fat oxidation from glucagon component
Comparison
| Feature | Semaglutide | Tirzepatide | Retatrutide | |---------|-------------|-------------|-------------| | Receptors | GLP-1 | GIP + GLP-1 | GIP + GLP-1 + Glucagon | | Max Weight Loss | ~17% | ~22% | ~24% |
---
*For educational and research purposes only.*